ADA

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin

Top

Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380(9840):475-483. A recent position statement from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) cites metformin as the optimal first-line drug for diabetes treatment. However, the statement acknowledges that limited data exist regarding treatments to be used beyond metformin.

Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity

Top

Cohen RV, Pinheiro JC, Schiavon CA, Salles JE, Wajchenberg BL, Cummings DE. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care. 2012;35:1420-1428. The authors of the current prospective study sought to examine the potential benefits of laparoscopic Roux-en-Y gastric bypass (LRYGB) among those with BMI 30-34.9 kg/m2 (class I obesity) and type 2 diabetes.

Impaired Glucose Tolerance and Obesity as Effect Modifiers of Ethnic Disparities of the Progression to Diabetes: The San Antonio Heart Study

Top

Lorenzo C, Lee R, Haffner SM. Impaired Glucose Tolerance and Obesity as Effect Modifiers of Ethnic Disparities of the Progression to Diabetes: The San Antonio Heart Study. Diabetes Care. 2012 Aug 24. Epub ahead of print. The Diabetes Prevention Program (DPP) reported no racial/ethnic differences in the incidence of diabetes in individuals with impaired glucose tolerance (IGT). Therefore, it has been hypothesized that factors associated with racial/ethnic disparities act prior to the development of IGT.

Nonnutritive Sweeteners: Current Use and Health Perspectives: A Scientific Statement from the American Heart Association and the American Diabetes Association

Top

Gardner C, Wylie-Rosett J, Gidding SS, Steffen LM, Johnson RK, Reader D, Lichtenstein AH. Nonnutritive Sweeteners: Current Use and Health Perspectives: A Scientific Statement from the American Heart Association and the American Diabetes Association. On behalf of the American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Disease in the Young, and the American Diabetes Association. Diabetes Care. 2012 Aug;35(8):1798-1808. Epub 2012 Jul 9.

ARIC Study: Examining Hypertension Risk Based on A1C

Top

Bower JK, Appel JL, Matsushita K, et al. ARIC Study: Examining Hypertension Risk Based on A1C. Diabetes Care. 2012;35:1031-1037. Bower and colleagues examined the role of A1C as a predictor of hypertension among subjects with and without diabetes in the Atherosclerosis Risk in Communities (ARIC) study.

EUREXA: Exenatide vs Glimepiride for Prevention of Glycemic Deterioration Among Those with Type 2 Diabetes and Metformin Failure

Top

Exclusive! Expert commentary from Burton E. Sobel, MD, on the EUREXA trial. Gallwitz B, Guzman J, Dotta F, et al. EUREXA: Exenatide vs Glimepiride for Prevention of Glycemic Deterioration Among Those with Type 2 Diabetes and Metformin Failure. Lancet. 2012;379(9833):2270-2278. The European Exenatide (EUREXA) trial is an open-label, randomized, controlled trial comparing add-on exenatide with glimepiride for durability of glycemic control among subjects with type 2 diabetes that is inadequately controlled with metformin monotherapy.

EASIE: Insulin Glargine vs Sitagliptin in Insulin-naïve Patients with Type 2 Diabetes Uncontrolled on Metformin

Top

Continuous coverage of ADA 2012. Aschner P, Chan J, Owens DR, et al; on behalf of the EASIE investigators. EASIE: Insulin Glargine vs Sitagliptin in Insulin-naïve Patients with Type 2 Diabetes Uncontrolled on Metformin. Lancet. 2012;379(9833):2262-2269. The Evaluation of insulin glargine versus Sitagliptin in Insulin-naïve patients (EASIE) trial is a multicenter, randomized, parallel, open-label trial that examined the efficacy, safety, and tolerability of a basal insulin, insulin glargine, vs a DPP-4 inhibitor, sitagliptin, among insulin-naïve patients with type 2 diabetes that was uncontrolled on metformin.

DPPOS: Effect of Regression from Prediabetes to NGR on Long-term Diabetes Risk Reduction

Top

Continuous coverage of ADA 2012. Perreault L, Pan Q, Mather KJ, et al; for the Diabetes Prevention Program Research Group. DPPOS: Effect of Regression from Prediabetes to NGR on Long-term Diabetes Risk Reduction. Lancet. 2012;379(9833):2243-2251. This report sought to quantify and predict diabetes risk reduction during the long-term follow-up to the Diabetes Prevention Program (DPP), the Diabetes Prevention Program Outcomes Study (DPPOS).

ORIGIN: Insulin Glargine and CVD and Other Outcomes in Dysglycemia

Top

Exclusive! Expert commentary from Silvio E. Inzucchi, MD, on the ORIGIN glargine trial. ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. ORIGIN: Insulin Glargine and CVD and Other Outcomes in Dysglycemia. N Engl J Med. 2012;367(4):319-328. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is a randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes

ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia

Top

Exclusive! Video commentary from Vivian A. Fonseca, MD. ORIGIN Trial Investigators, Bosch J, Gerstein HC, et al. ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia. N Engl J Med. 2012;367(4):309-318. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is a randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes.

1 2 3 4 5 6 7 8 Next